Monitor future Form 4 filings for any open-market purchases or grants that would signal insider conviction. No immediate read-through from this initial filing.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $13.08entry
- T+1 · 11d ago +16.21%α +15.90% · $15.20
- T+5 · 5d ago +27.29%α +24.00% · $16.65
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Menassie Taddese filed a Form 3 initial statement of beneficial ownership and a related power of attorney, reporting zero beneficial ownership of Xeris Biopharma Holdings, Inc. securities as of the event date. This is a routine filing by a new director with no securities held, carrying no material financial impact.
Key Facts
- Menassie Taddese filed a Form 3 initial statement of beneficial ownership on 2026-11-04, with a period of report of 2026-11-02.
- The filing reports zero beneficial ownership: 0 shares, 0 derivative securities.
- A power of attorney (Exhibit 24) was filed, appointing John Shannon, Beth Hecht, and Steve Pieper as attorneys-in-fact for Section 16 filings.
- Taddese's business address is listed as Xeris Biopharma's Chicago headquarters, and his mailing address is in Canonsburg, PA.
Financial Impact
No financial impact; zero shares reported.
Risk Factors
- No risks identified from this routine filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001867096-26-000103 |
| Document: 0001867096-26-000103-index-headers.html | 0001867096-26-000103 |
| Document: 0001867096-26-000103-index.html | 0001867096-26-000103 |
| Document: 0001867096-26-000103.txt | 0001867096-26-000103 |
Track record
25 reports on XERS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +45.52% at T+60 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $15.86 Now $16.70 +5.30% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $15.20 Now $16.70 +9.87% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago 3 Neutral 2/10 Viewing Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $10.35 Now $16.70 +61.35% settles Dec 2
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $10.17 Now $16.70 +64.21% settles Dec 1
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $10.71 Now $16.70 +55.93% settles Nov 30
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $9.77 to $16.52 Now $16.70 +70.93% ▲ +69.09% +70.36% vs SPY
- Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $10.13 to $10.71 Now $16.70 +64.86% ▲ +5.73% +8.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers